Elvina Almuradova/LinkedIn
Mar 29, 2025, 21:34
Elvina Almuradova: Pembrolizumab plus CRT as the New Standard in Locally Advanced Cervical Cancer
Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared a post on X:
“Updated results confirm Pembrolizumab plus CRT as the new standard in locally advanced cervical cancer!
- 32% reduced progression risk
- 40% reduced PFS2 risk
- 33% reduced death risk
3-year OS: 82.6% vs 74.8%
3-year PFS: 62.7% vs 54.5%”
More posts featuring Elvina Almuradova.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 2, 2025, 19:03
Apr 2, 2025, 18:42
Apr 2, 2025, 18:29
Apr 2, 2025, 18:23
Apr 2, 2025, 18:14
Apr 2, 2025, 18:01
Apr 2, 2025, 17:58